Zubsolv generic
Zubsolv is an opioid dependency treatment medication owned by Orexo Us Inc. The drug, which was authorized for market use on July 3, 2013, contains active ingredients Buprenorphine Hydrochloride and Naloxone Hydrochloride. Zubsolv holds a total of 10 patents to its credit.
When will Zubsolv generic be available?
The generics for Zubsolv can possibly be released after the last patent's expiry on September 18, 2032. This patent is related to the drug's formula designed to deter misuse, steering it towards opioid dependence treatment.
Zubsolv uses
Zubsolv has been designed to treat opioid dependence through sublingual or buccal administration of active ingredients Buprenorphine and Naloxone. These ingredients work together to alleviate symptoms of opioid dependence while deterring misuse.
Zubsolv patent expiration
Zubsolv has ten patents protecting it against generic versions until September 18, 2032. The majority of these patents are regarding the drug's abuse-resistant composition. For more about when Zubsolv generics may hit the market, refer to the patent expiry details below. Below are the details of the patent: